Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 20/20 | 1.00 |
| ▸ | MTOR | P42345 | 20/20 | 1.00 |
| ▸ | PIK3CG | P48736 | 10/20 | 1.00 |
| ▸ | ATR | Q13535 | 6/20 | 0.87 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.73 |
| ▸ | RICTOR | Q6R327 | 1/20 | 0.67 |
| ▸ | RPTOR | Q8N122 | 1/20 | 0.67 |
| ▸ | MAPKAP1 | Q9BPZ7 | 1/20 | 0.67 |
| ▸ | MLST8 | Q9BVC4 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3991768 | 0.94 | PIK3CA (0.88) | PIK3CAMTORPIK3CGATRAURKB | |
| SCHEMBL3984945 | 0.93 | PIK3CA (1.00) | PIK3CAMTORPIK3CGATRRICTOR | |
| SCHEMBL3983641 | 0.92 | PIK3CA (0.86) | PIK3CAMTORPIK3CGATRAURKB | |
| SCHEMBL3991759 | 0.92 | PIK3CA (0.89) | PIK3CAMTORPIK3CGATRRICTOR | |
| SCHEMBL54564 | 0.90 | PIK3CA (0.82) | PIK3CAMTORPIK3CGATR | |
| SCHEMBL3992094 | 0.90 | PIK3CA (1.00) | PIK3CAMTORPIK3CGATR | |
| SCHEMBL3915027 | 0.90 | PIK3CA (1.00) | PIK3CAMTORPIK3CGATRAURKB | |
| SCHEMBL4998371 | 0.90 | PIK3CA (0.85) | PIK3CAMTORPIK3CGATRRICTOR | |
| SCHEMBL3994177 | 0.89 | PIK3CA (0.87) | PIK3CAMTORPIK3CGATRAURKB | |
| SCHEMBL3992157 | 0.89 | PIK3CA (0.85) | PIK3CAMTORPIK3CGATR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2078021-A2 | PYRAZOLOPYRIMIDINE ANALOGS AND THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS | Wyeth a Corporation of the State of Delaware (US) | 2009-07-15 | — | — | EP | claimed |
| WO-2008115974-A2 | PYRAZOLOPYRIMIDINE ANALOGS AND THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS | WYETH (US) | 2008-09-25 | — | — | WO | claimed |
| US-20080234262-A1 | PYRAZOLOPYRIMIDINE ANALOGS AND THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS | WYETH (US) | 2008-09-25 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234262-A1 | PYRAZOLOPYRIMIDINE ANALOGS AND THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS | MTOR, PIK3CA, PDPK1 | PIK3CA 2/4885MTOR 1/4885PIK3CG 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.